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Therapeutic potential of
histamine H3 receptor
agonists and antagonists
Rob Leurs, Patrizio Blandina, Clark Tedford and 
Henk Timmerman
The histamine H3 receptor was discovered 15 years
ago, and many potent and selective H3 receptor
agonists and antagonists have since been developed.
Currently, much attention is being focused on the
therapeutic potential of H3 receptor ligands. In this
review, Rob Leurs, Patrizio Blandina, Clark Tedford
and Henk Timmerman describe the available H3
receptor agonists and antagonists and their effects in a
variety of pharmacological models in vitro and in vivo.
The possible therapeutic applications of the various
compounds are discussed.
Histamine mediates its action via three distinct receptor
subtypes, H1, H2 and H3 (Refs 1, 2). The subclassification
of the histamine receptors by the pioneering work of Ash
and Schild3, Black et al.4 and Arrang et al.5 has been sup-
ported by recent molecular biological approaches1,2. The
demonstration of the existence of both H1 and H2 recep-
tors opened important new avenues for successful treat-
ment of allergic conditions (H1 receptor antagonists) and
gastric ulcers (H2 receptor antagonists). Although con-
siderable progress has been made in the medicinal chem-
istry of H3 receptor ligands and the understanding of 
the role of the H3 receptor in (patho)physiology, no H3
receptor-related drugs have yet been introduced.
The H3 receptor was discovered originally on his-
tamine-containing neurones as a presynaptic receptor
regulating the release and synthesis of histamine5 (Box 1).
In the mammalian brain, histamine-containing cell bodies
are located in the tuberomammillary nucleus of the pos-
terior hypothalamus and project to most cerebral areas6,7,
indicating that H3 receptor ligands can potentially affect
a variety of brain functions. Moreover, H3 receptors not
only act as autoreceptors, but are also involved in the
presynaptic regulation of the release of acetylcholine,
dopamine, GABA, glutamate, noradrenaline and 5-HT
(Box 1). Recent data show that H3 receptors are not con-
fined to the brain, but also play a modulatory role in
peripheral neurotransmission (e.g. in the gastrointestinal
tract, the cardiovascular system and the airways)1,2,8,9. 
Selective H3 receptor agonists and antagonists
Since the initial discovery of the H3 receptor in 1983
(Ref. 5), major progress in the development of H3 receptor
agonists and antagonists has been made. Several potent
and selective agonists are currently available10,11. Methyl-
ation of the a-carbon atom of the ethylamine side-chain of
histamine leads to the potent H3 receptor agonist R-(a)-
methylhistamine (Fig. 1). In combination with its less
active S-isomer, this compound has been very useful for
the pharmacological characterization of H3 receptor-
mediated effects10. Further H3 agonists are produced if the
amine function of histamine is replaced by an isothiourea
group (imetit), an amidine moiety (SKF91606) or incorpo-
rated in a ring structure (immepip) (Fig. 1)12–15. Because of
its early availability, R-(a)-methylhistamine has been used
extensively in vitro and in vivo. Recently, high affinity of 
R-(a)-methylhistamine for the histamine-metabolizing
enzyme histamine-N-methyltransferase was observed16.
Methylation of the imidazole ring of R-(a)-methylhis-
tamine by histamine-N-methyltransferase results in a very
short plasma half-life in humans (3 min), which, combined
with the high polarity of R-(a)-methylhistamine, strongly
limits its brain penetration. With the development of a
series of R-(a)-methylhistamine prodrugs (Fig. 1), the lat-
ter problem of penetration is largely eliminated17. The
azomethine group in BP294 (Fig. 1) prevents the methyl-
ation of the imidazole ring by histamine-N-methyltrans-
ferase and improves oral bioavailability. In humans, a sin-
gle oral dose produces long-lasting (>24 h) plasma levels
of both BP294 and R-(a)-methylhistamine (after non-enzy-
matic cleavage in blood plasma)16. Moreover, selective
substitution of the azomethine group allows substantial
brain penetration [e.g. FUB307 (Fig. 1)]18. 
Many potent H3 receptor antagonists have also been
developed. The prototypic H3 receptor antagonist, thio-
peramide (Fig. 2)19, has a nanomolar affinity for the H3
receptor and penetrates fairly well into the brain. Despite
its widespread use, caution should be taken since thio-
peramide also has some affinity for the 5-HT3 receptor20
and probably interacts with neuronal GABA transport21.
Replacement of the thiourea side-chain of thioperamide
has led to a wide variety of H3 receptor antagonists10,11.
Incorporation of an isothiourea moiety in the side-chain
gives the highly potent H3 receptor antagonist clobenpro-
pit (Fig. 2), which was developed as a N-substituted deriva-
tive of imetit14. This antagonist is tenfold more potent than
thioperamide in vitro, but has a reduced brain penetration.
To increase central effectiveness and to overcome potential
toxicological problems connected with the thiourea and
isothiourea moieties, these groups have been replaced by
several side-chains with other polar groups (e.g. ureas,
amines, amides, ethers, carbamates and oxadiazoles) to
produce the H3 receptor antagonists FUB181, GR175737,
GT2016 and UCL1199 (Fig. 2)11. Many of these ligands
show an improved brain penetration and high effective-
ness in vivo in rodents. Particularly remarkable is the recent
Box 1. Modulation of CNS neurotransmission by histamine H
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In 1983, Arrang et al.1 described a new histamine recep-
tor subtype that modulated the K+-evoked release of
[3H]histamine from cerebral cortex slices preloaded
with [3H]-L-histidine. This histamine H3 autoreceptor
was stimulated by low concentrations of histamine,
insensitive to selective H1 and H2 receptor agonists
and the inhibition by histamine was antagonized 
by both the H2 receptor antagonist burimamide 
and the H2 receptor agonist impromidine1. After the
establishment of the unique pharmacology of the H3
autoreceptor, its presence was detected in several
other brain areas2,3 (Fig.), including the human cer-
ebral cortex4. The persistence of H3 receptor effects in
the presence of tetrodotoxin and experiments with
synaptosomes indicate the presynaptic location of the
H3 autoreceptor2. Histamine exerts a tonic influence on
presynaptic H3 receptors both in vitro and in vivo2,3.
Consequently, systemic administration of H3 receptor
agonists and antagonists reduces and increases 
neuronal histamine release, respectively, leading to
Fig. Schematic diagram, showing the localization of some of the functional responses of the H3 receptor in the brain. In a variety of brain regions of
several species, the H3 receptor modulates the release of several important neurotransmitters7. Modified, with permission, from a drawing by 
E. Schlicker.
development of GT2227 (Fig. 2). This H3 receptor antag-
onist is active both in vitro and in vivo22, although a polar
group is lacking in the side-chain. The high activity of this
ligand suggests that the molecular architecture of the H3
receptor is distinct from that of the H1 and H2 receptor.
Peripheral effects with therapeutic potential
The H3 receptor can modulate a variety of functions of
important peripheral organs. In cats, dogs and rabbits,
but not in rats, H3 receptor activation inhibits gastric acid
secretion induced by food, pentagastrin or 2-deoxy-D-
glucose9. This effect is secondary to the H3 receptor-
induced inhibition of the release of acetylcholine, his-
tamine or somatostatin from vagal nerve endings,
enterochromaffin-like (ECL) cells and D cells (somato-
statin-releasing cells), respectively9. Because of the 
histamine tone in the stomach, H3 receptor antagonists
enhance gastric acid secretion induced by submaximal
doses of 2-deoxy-D-glucose and pentagastrin9.
Despite its lack of effect on gastric acid secretion in the
rat, R-(a)-methylhistamine (1–100 mg kg–1 i.p.) shows a
remarkable gastroprotective effect in this species. Gastric
mucosal lesions induced by ethanol, aspirin or stress are
inhibited effectively by R-(a)-methylhistamine, but this
effect is only partially sensitive to thioperamide and
clobenpropit, indicating that a non-H3 receptor compo-
nent is also involved9. The mechanism of protection
seems to involve the mucosal layer, since histological
studies show that R-(a)-methylhistamine increases the
number of mucous granules in surface and neck cells and
promotes rapid re-epithelization9.
A role for H3 receptors in the regulation of inflamma-
tory processes has recently been found. In rodents,
BP294 causes an inhibition of capsaicin-induced plasma
extravasation and zymosan-induced paw swelling16.
These effects are attributed to the expression of
inhibitory H3 receptors on sensory C fibres, which, in
concert with histamine-releasing mast cells, act as a 
urotransmission by histamine H3 receptors
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increased and decreased histamine levels in brain tis-
sue, respectively3. Microdialysis experiments that
measure the release of endogenous histamine in the 
rat hypothalamus also indicate a tonic H3 receptor-
mediated inhibition at the autoreceptor5. 
The development of the selective H3 receptor agonist
(R)-a-methylhistamine and antagonist thioperamide
allowed the demonstration of the modulation of a vari-
ety of neurotransmitter systems via H3 heterorecep-
tors. In the rat hypothalamus, H3 receptors inhibit, for
example, the release of 5-HT and noradrenaline6.
Release of both these neurotransmitters is also reduced
by presynaptic H3 receptors in cerebral cortex slices of
several other species7 (Fig.). Experiments in vitro show
that H3 receptor activation also inhibits the release of
acetylcholine in the rat enthorinal cortex8, although a
presynaptic localization of the H3 receptor is unlikely
as inhibition of K+-evoked release of [3H]acetylcholine
from synaptosomes by H3 receptor agonists was not
detectable9. In mouse striatal tissue, dopamine release
is affected by H3 receptor activation10, and dopamine
D1 receptor-induced release of GABA from slices of rat
striatum11 and substantia nigra12 is effectively inhib-
ited by H3 receptor activation on GABA-containing
nerves. Finally, in a recent electrophysiological study
using rat hippocampal slices, strong evidence for a
presynaptic H3 receptor-mediated regulation of gluta-
mate release in the dentate gyrus was provided13.
Histamine H3 receptor ligands do not substantially
affect brain noradrenaline, dopamine or 5-HT levels in
vivo14. Interestingly, acetylcholine release in both the
rat hippocampus15, cerebral cortex16 and ventral stria-
tum can be modulated by H3 receptor ligands17. In the
hippocampus, histamine, released from histamine-
containing nerve terminals, stimulates acetylcholine
release via H2 receptors15. Interference with histamine-
mediated neurotransmission via systemic adminis-
tration of H3 receptor agonists or antagonists decreases
or increases the hippocampal acetylcholine release,
respectively15. In the cerebral cortex of freely moving
rats, activation of postsynaptic H3 receptors stimulates
the release of GABA (Fig.), which, in turn, inhibits the
depolarization-induced release of acetylcholine18. The
reduced acetylcholine release in the cerebral cortex
after systemic administration of H3 receptor agonists is
accompanied by an impaired performance of the rats
in the object-recognition test and passive-avoidance
response16.
These data show that the H3 receptor is widely dis-
tributed throughout the CNS. This correlates well with
autoradiographic studies19, which also indicate that
the presence of H3 receptors is not solely restricted to
the histamine-containing neurones.
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negative-feedback system for the release of neuro-
peptides16. A similar feedback mechanism exists in the
rat, guinea-pig and rabbit lung and in the rat dura 
mater, suggesting a beneficial effect of H3 receptor 
agonists in neurogenic airway inflammation23–25 and also
in migraine26,27.
In the cardiovascular system, H3 receptor activation
has been reported to inhibit sympathetic neurotransmis-
sion in a variety of preparations8, including the human
right atrium28. In isolated guinea-pig hearts, H3 receptor
agonists reduce substantially the noradrenaline release
in early myocardial ischaemia. Moreover, reperfusion-
induced arrhythmias are inhibited by 50% by H3 recep-
tor stimulation29. In the same preparation, H3 receptor
activation also inhibits the release of calcitonin-gene-
related peptide (CGRP) from sensory C fibres30. Since
CGRP release is elevated in humans in severe conditions
such as septic shock, heart failure and acute myocardial
infarction, H3 receptor agonists might be of therapeutic
use in these conditions29,30.
Sleep and wakefulness
The presence of histamine-containing cell bodies in
the tuberomamillary nucleus of the posterior hypothala-
mus (an area involved in the maintenance of wakeful-
ness) and their projections to the cerebral cortex suggest
a role of histamine in the modulation of the arousal state
and sleep–wake cycle. Lesions of the posterior hypothala-
mus are known to produce sleep in rats, cats and mon-
keys31, and neurochemical and electro-physiological
studies indicate that the activity of histamine-containing
neurones is maximal during periods of wakefulness and
is suppressed by barbiturates and other hypnotics32.
Intraventricular histamine induces the appearance of an
arousal electroencephalogram (EEG) pattern in rabbits33.
Moreover, histamine release in the rat hypothalamus 
in vivo shows a circadian rhythm, with higher histamine
release in periods with high locomotor activity34. 
Conversely, inhibition of histidine decarboxylase has
been shown to impair waking in rats35. Strong evidence
indicates that the effects of histamine on sleep param-
eters are mediated by the H1 receptor, explaining the
sedative side-effects of CNS-penetrating H1 receptor
antagonists31.
Modulation of histamine-mediated neurotransmis-
sion with H3 receptor agonists [e.g. R-(a)-methyl-
histamine and BP294] results in an increase of the slow-
wave sleep in rat and cats31,36,37. Increased wakefulness,
decreases in rapid eye movement (REM) and slow-wave
sleep and increased locomotion are observed after sys-
temic application of H3 receptor antagonists36–38. 
Cognition and memory processes
Dysfunctions of acetylcholine-mediated neurotrans-
mission are considered to underlie the cognitive decline
associated with ageing and Alzheimer’s disease. However,
changes typical of ageing and Alzheimer’s disease occur
within the context of alterations of other neurotransmitter
systems, including histamine39,40. Histamine levels in the
hypothalamus, hippocampus and temporal cortex have
been found to be significantly lower in brains from patients
with Alzheimer’s disease compared with controls40. More-
over, in Alzheimer’s disease, the characteristic neurofibril-
lary tangles co-localize with histamine-containing neur-
ones in the posterior hypothalamus41. 
There is also direct evidence that histamine-mediated
neurotransmission plays an important role in learning
and memory. Histamine has been shown to influence
synaptic plasticity in hippocampal slices42, and to
increase recall in a step-down inhibitory avoidance task
when given immediately post-training43. Similarly, pre-
testing administration of histamine enhances cognitive
performance of rats in an active avoidance task while H1
receptor antagonists impair memory retention44,45.
Although histamine might affect cognition on its own,
neurochemical studies suggest that histamine also
modulates the activity of cholinergic neurons (Box 1).
High levels of H3 receptors are found in the frontal 
cortex and hippocampus, implying a role in higher learn-
ing function46. Microdialysis studies show that acti-
vation of cortical H3 receptors by local and systemic 
(5 mg kg–1 s.c.) administration of imetit and R-(a)-methyl-
histamine reduces K+-evoked release of acetylcholine
from the cortex of freely moving rats (Fig. 3)47. The cog-
nitive performance of rats in object recognition and a
passive-avoidance response is strongly impaired by simi-
lar doses of these H3 receptor agonists (Fig. 3)47. More-
over, immepip impairs performance in an olfactory
social-memory test in rats48. Conversely, a beneficial
effect of R-(a)-methylhistamine has been reported in
rodent spatial learning and memory, assessed using a
water maze49. Differences among the behavioural tests
used may explain this discrepancy. Spatial learning is a
primary function of the rodent hippocampus50, while
object recognition, passive-avoidance response and the
olfactory social-memory test serve to measure a form of
episodic memory, possibly localized in the frontal cortex.
These responses are severely impaired by lesions of the
basalocortical system, which only slightly disturb water-
maze performance51. 
Studies with thioperamide and clobenpropit suggest
that H3 receptor antagonists may provide a novel
approach to improve cognitive deficits. Thioperamide
exerts procognitive activity in the olfactory social-
memory test48, but other studies report that the procog-
nitive effects of H3 receptor antagonists only become
fully evident when behavioural deficits are pronounced.
Thioperamide improves significantly the response
latency in a passive-avoidance response in senescence-
accelerated mice, but is ineffective in normal-rate ageing
mice52. Other studies report that administration of thio-
peramide (20 mg kg–1 i.p.) or clobenpropit (20 mg kg–1
i.p.) to mice impaired by scopolamine (1 mg kg–1 i.p.)
attenuates the amnesic effects of scopolamine in the 
elevated plus-maze test and the step-through passive-
avoidance test53,54. 
TiPS – May 1998 (Vol. 19) 1 8 1
R E V I E W
Attention-deficit hyperactive disorder
Attention-deficit hyperactivity disorder (ADHD) is a
developmental disorder with underlying emotional, atten-
tional and learning disabilities. The disorder has an onset
in early childhood (there are approximately three million
sufferers in the USA) and over 50% of those children diag-
nosed with ADHD will continue to experience attentional
problems as adults55. Underlying abnormalities in
monoamine neurotransmitters appear to significantly con-
tribute to the learning and motor disturbances in ADHD
patients55,56. The psychostimulants methylphenidate, 
dextroamphetamine and pemoline provide symptomatic
relief but also produce several serious side-effects.
The use of H3 receptor antagonists can be envisioned in
attentional disorders on the basis of the previously
described wake-promoting or vigilant profiles seen by
EEG, the procognitive properties in animal models of learn-
ing and memory, and the direct effects on neurotransmitter
release, particularly acetylcholine, noradrenaline and
dopamine. Immature developmental models have been
described in which impairments in cognitive processes or
motor patterns are seen that are similar to those observed 
in ADHD (Refs 57, 58). In an immature rat model, pre-
training administration of the selective H3 receptor antag-
onist GT2016 was evaluated at doses (5–30 mg kg–1 i.p.) that
paralleled cortical H3 receptor-occupancy profiles and
enhanced cortical histamine release in vivo59. GT2016 sig-
nificantly improved the rate of acquisition in a multi-trial
passive-avoidance-response task. Methylphenidate pro-
vided similar improvements in learning rates in immature
rat pups60,61. These data demonstrate that H3 receptor
antagonists may be of use in the treatment of ADHD. Not
only do these drugs improve the cognitive deficits, but they
also normalize motor disturbances60.
Epilepsy
Almost 50 years ago, the first clinical indications sug-
gesting the involvement of central histamine-mediated
neurotransmission in epilepsy were reported62,63. In
epileptic patients and healthy young children (especially
of pre-school age), several brain-penetrating H1 receptor
antagonists occasionally induce convulsions62–64. More-
over, direct H1 receptor activation or modulation of CNS
histamine levels by L-histidine loading, inhibition of his-
tamine synthesis or metabolism in rodents has indi-
cated that histamine may be an endogenous anticonvul-
sant64. A role for the H1 receptor in epilepsy is further
supported by an increased H1 receptor density (10–50%)
in the focus of epileptic discharges in the temporal 
neocortex of nine patients with complex partial seizures,
as measured by positron emission tomography (PET)
studies with [11C]doxepin65. 
As mentioned before, presynaptic control via the 
H3 receptor is an important regulatory mechanism of 
histamine-mediated neurotransmission. Recent data indi-
cate that various H3 receptor antagonists (thioperamide,
clobenpropit and AQ0145) decrease the seizure suscepti-
bility of electrically induced convulsions in mice66–68 by
increasing endogenously released histamine in the brain.
The anticonvulsant effect of these drugs is antagonized
by pretreatment with H3 receptor agonists or the H1
receptor antagonist mepyramine66–68. These findings
support the anticonvulsive effect of endogenous his-
tamine and suggest that H3 receptor antagonists could 
represent a new approach to the development of
antiepileptic drugs, especially in young children.
Fig. 1. Structures of selective H3 receptor agonists and two prodrugs of (R)-a-methylhistamine,
BP294 and FUB307. The pD2 values (pD2 = the negative log of the molar concentration of agon-
ist giving 50% of the maximal effect) obtained for the H3 receptor-mediated inhibition of neuro-
genic contractions of the guinea-pig jejunum are indicated for the H3 receptor agonists13,15.
Fig. 2. Structures of selective H3 receptor antagonists. The pKi values are indicated11.
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Obesity
Recently, the approval of dexfenfluramine by the
Food and Drug Administration was met with great
expectations for the treatment of morbid obesity. How-
ever, atrial valve problems observed in the ‘fen/phen’
(dexfenfluramine and phentermine) combination ther-
apy have led to the removal of the product and have
severely limited treatment options. Many new therapies
under development for obesity are based on their action
at the hypothalamic level (i.e. neuropeptide Y receptor
antagonists, cholecystokinin receptor agonists, noradren-
aline or 5-HT releasers and uptake inhibitors)69. 
A number of studies suggest that histamine can also
suppress appetite and that histamine-containing neur-
ones in the hypothalamus participate in the endogenous
suppression of food intake. Intracerebroventricular
injections of histamine depress feeding in rats, whereas
the application of H1 receptor antagonists or depletion of
endogenous histamine by inhibition of histidine decar-
boxylase elicits a feeding response70. Moreover, chronic
treatment of humans with CNS-penetrating H1 receptor
antagonists leads to weight gain. It is generally consid-
ered that histamine activates postsynaptic H1 receptors
in the ventromedial nucleus (VMH) (and possibly also
the paraventricular nucleus) of the hypothalamus to
suppress food intake70. In addition, H3 receptors have
been identified with moderate density in the VMH (Ref.
46). In line with these observations, administration of
thioperamide i.c.v. suppresses food intake, which is
consistent with the drug-induced increase in histamine
release in rats. This effect on appetite can be blocked by
the concomitant administration of an H1 receptor antag-
onist70. In addition, the anorectic actions of both amylin
and bombesin are mediated by the histamine transmitter
system71,72. Furthermore, dexfenfluramine increases his-
tamine release in the rat hypothalamus, which poten-
tially contributes to its anorectic effects73. Recently, dys-
functions in histamine-mediated neurotransmission
have been identified in the obese Zucker rat, a genetic
model for obesity74. The role of hypothalamic histamine
in regulating body-weight homeostasis is thus very com-
pelling, and supports the clinical use of H3 receptor
antagonists in the treatment of obese conditions.
Concluding remarks
Important progress has recently been made in the
understanding of the role of the H3 receptor. Clear indi-
cations for the potential therapeutic use of H3 receptor ag-
onists and antagonists are now available, and clinical trials
are in progress or being planned. For H3 receptor agonists
especially, the feedback mechanism on sensory C fibres
and resultant anti-inflammatory effects suggest a poten-
tial peripheral application in the treatment of asthma,
migraine, cardiac disorders and inflammatory disorders,
such as arthritis and bowel diseases. The potential for
impairment of cognitive performance or the induction of
sedation may restrict their use; thus, H3 receptor agonists
with limited accessibility to the CNS should be used in
these indications. Currently, these hypotheses are being
evaluated in clinical trials using BP294 (Ref. 16).
The CNS effects of the H3 receptor antagonists make
them interesting candidates for testing in several disorders
of the CNS. These drugs show potential therapeutic effects
in models of obesity and epilepsy. The observations that
H3 receptor antagonists have beneficial effects on learning
parameters in both pharmacological and natural models 
of memory impairments are also intriguing. The possible 
relevance of these findings to diseases such as age-
related memory disorders, Alzheimer’s disease and
ADHD is certainly worthy of consideration and awaits
confirmation from clinical trials. Interestingly, tacrine,
which is used successfully in some patients with
Alzheimer’s disease, is more active as an inhibitor 
of histamine-N-methyltransferase than acetylcholine
esterase both in vitro and in vivo75,76. In view of this effect
0
40
80
120
160
0
0.5
1.0
1.5
2.0
S 2
/S
1
La
te
nc
y 
(s)
saline               RAMH               imetit
5 mg kg21 i.p.     5 mg kg21 i.p.
saline               RAMH              imetit
5 mg kg21 i.p.     5 mg kg21 i.p.
*
*
*
*
a
b
Fig. 3. Effects of systemic administration of the H3 receptor agonists 
(R)-a-methylhistamine (RAMH) and imetit on a: acetylcholine release in
the cerebral cortex of freely moving rats as measured by microdialysis;
and b: the cognitive performance in a passive-avoidance paradigm. The
effects of the agonists on the acetylcholine release are expressed as 
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on histamine metabolism, the combination of tacrine and
an H3 receptor antagonist could be beneficial in these
conditions75. 
The highly localized CNS distribution of the H3 recep-
tor77 suggests that limited peripheral side-effects will be
seen after treatment with an H3 receptor antagonist. 
Furthermore, peripheral histamine-mediated tone is nor-
mally minimal, and the H3 receptor thus is mainly quies-
cent under normal physiological conditions. Indeed, no
cardiovascular8 or neuroendocrine effects78 have been
reported after treatment with H3 receptor antagonists.
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